President & CEO
Genelux Corporation

Thomas Zindrick, JD

Tom Zindrick, an experienced life sciences and biotechnology executive with a career spanning more than 20 years, joined Genelux Corporation as President and CEO in May 2014. Mr. Zindrick retired from Amgen Inc in 2009 after a distinguished 16 year career, and has since served as CEO of Amitech Therapeutic Solutions, Inc., a La Jolla, California based discovery and drug development company focused on commercializing allosteric kinase inhibitors, as well independent consultant to Genelux Corporation.

During his career at Amgen, he held positions of increasing responsibility, including Vice President, Associate General Counsel, and Chief Compliance Officer. As Vice President, Associate General Counsel, Mr. Zindrick led intellectual property, licensing and regulatory law teams, and served on cross-functional business and product development teams. These teams were responsible for acquisitions totaling over twenty billion dollars and the licensing and development of six therapeutic products and numerous clinical candidates. As Chief Compliance Officer, he reported to the Board of Directors and led the Corporate Compliance Program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company.

Mr. Zindrick received his J.D. from the University of Illinois College of Law and a BA in Biology from North Central College in Naperville, Illinois.

Chief Medical Officer, Genelux Corporation

Paul Scigalla, MD, PHD

A physician and medical researcher with more than 30 years of experience in clinical oncology product development, Dr. Paul Scigalla joined Genelux Corporation in September 2011 as the company’s Chief Medical Officer. He is responsible for providing strategic direction of the company’s Clinical Program to secure expeditious market approval for current and future investigational product candidates.

A native of Germany, Paul Scigalla received his medical training at Humboldt University in Berlin, graduating in 1970. After a fellowship in pediatric nephrology, Dr. Scigalla specialized in anemia in children with end-stage renal failure, earning his Ph.D. for research in the regulatory mechanism of erythropoiesis in end-stage renal failure in 1982. After 14 years in academic clinical practice, principally spent at the Pediatric Clinic of the Free University in Berlin, Dr. Scigalla entered the pharmaceutical industry in 1984. As head of Clinical Research for nephrology, oncology and bone metabolism at Boehringer Mannheim GmbH, he was responsible for the preclinical and clinical development of erythropoietin (licensed from Genetics Institute). This compound received licensing approval in Europe in 1988, only six years following discovery of the protein. In 1992, Dr. Scigalla was appointed Professor of Medicine at the University of Heidelberg. He later served as Boehringer Mannheim Senior Vice President and head of Global Development Therapeutics. Amongst many projects, he coordinated the development of ibandronate, a bisphosphonates for the treatment of bone metastases. Since leaving Boehringer Mannheim in 1998, Dr. Scigalla served as Senior Vice President at SUGEN, Inc., responsible for the clinical development of multiple receptor tyrosine kinase inhibitors, including semaxanib (currently in late-stage clinical trials for the treatment of cancer) and as Vice President Research Oncology, Pfizer Bedminster, New Jersey. Since August 2003, he has served as a consultant to several pharmaceutical companies in US, Japan and Europe.

Dr. Scigalla has published over 200 manuscripts in scientific journals and served as editor of 8 books focused on pediatric nephrology and erythropoiesis. Prof. Scigalla has major interests in the clinical development of novel biologically-targeted therapies.

Vice President Of Clinical Trial Operations

Tony Yu, PhD

Dr. Yu was an integral part of the initial scientific research that led to the formation of Genelux Corporation and was the Company’s first employee. He received a PhD in anatomy and biochemistry in 2002 from Loma Linda University and a BA from the University of Utah in 1995 after moving to the U.S. from his native China. After several years at the center of Preclinical research and development at Genelux, Dr. Yu now leads the Company’s Clinical Operations group, managing protocol development and overseeing all aspects of our human Clinical Trial program.